No. As of September 2026, sermorelin is not marketed as an FDA-approved medicine in the United States. FDA approved it twice, as Geref Diagnostic in December 1990 and Geref in September 1997, but EMD Serono discontinued both products in 2008 and the approvals were formally withdrawn in 2009. In 2013 FDA determined the withdrawal was not for reasons of safety or effectiveness. A pharmacy can still compound sermorelin on prescription, and WADA prohibits it at all times.
The table below shows sermorelin's position on the five registers that decide whether a compound is approved, compoundable or prohibited in sport, and each row carries the as-of date its Peptigrity source gives.
Register | Sermorelin's position | As of (Peptigrity source) |
|---|---|---|
FDA approval | Approved twice, both withdrawn. Geref Diagnostic (NDA 019863), December 1990, to evaluate the pituitary's growth-hormone-secretory capacity; Geref (NDA 020443), September 1997, to treat idiopathic growth-hormone deficiency in children. Both discontinued in 2008 and formally withdrawn in 2009. FDA determined in 2013 that Geref was not withdrawn for reasons of safety or effectiveness. | August 2026 — sermorelin compound page (last updated August 2026) and the regulatory snapshot (as of August 2026) |
FDA Category 2 bulk list | Not listed. Sermorelin is absent from FDA's Category 2 list. It reaches 503A compounding through the component-of-an-approved-drug prong, and FDA's 503B documentation footnotes "Sermorelin Acetate" as a component of FDA-approved drugs. | FDA page current 22 April 2026 — ipamorelin vs sermorelin vs tesamorelin |
PCAC review | No review on record. No Pharmacy Compounding Advisory Committee vote on sermorelin is recorded on Peptigrity, and it was not among the seven substances the committee reviewed on 23–24 July 2026. | Through the 23–24 July 2026 meeting — FDA regulation timeline (as of August 2026) |
WADA | Prohibited at all times under section S2.2.4 (growth-hormone-releasing factors), classified as non-specified. | WADA 2026 Prohibited List — compound page and the drug-testing guide |
Other jurisdictions | US approvals only on record, both withdrawn in 2009. Sermorelin's status in other countries is not assessed on Peptigrity. | Snapshot as of August 2026 |
Do you need a prescription for sermorelin?
Yes, for any lawful pharmacy supply. With both Geref products gone, sermorelin reaches patients in the United States through compounding pharmacies, which prepare it for a named patient when a licensed physician prescribes it. Research-grade sermorelin sold by third-party laboratories is a separate supply chain and is not a prescription product.
What a prescription cannot do is restore an approved label. Adult use of sermorelin was never FDA-approved: the approvals covered a diagnostic test and growth-hormone deficiency in children. This page states what published documents say. It is legal information, not legal advice, and anything touching your own circumstances belongs with a qualified professional.
Can a pharmacy compound sermorelin?
Yes, under one statutory prong, with one caveat. Under 21 U.S.C. § 353a(b)(1)(A), a bulk substance used in 503A compounding must comply with a USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulks list. Sermorelin qualifies as a component of an approved drug, and FDA's own 503B bulk substances documentation lists "Sermorelin Acetate" with a footnote marking it that way.
The caveat is the withdrawal. Both Geref approvals were formally withdrawn in 2009, and Peptigrity found no FDA document expressly resolving whether a withdrawn approval still satisfies the component prong. The 503B footnote implies the agency's answer; the final inferential step is not spelled out anywhere Peptigrity could locate. The compounding pathway has also been subject to FDA regulatory action during 2024–2026.
The evidence behind that route is thin. A December 2020 report prepared for FDA by the University of Maryland CERSI examined sermorelin's nomination for compounding and found two peer-reviewed studies meeting inclusion criteria, both 1996 diagnostic studies, zero survey responses, and no clinical practice guideline recommending sermorelin. Even a lawful compounded product carries FDA's own ceiling: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." The mechanics are in compounding pharmacy versus research peptide.
Where does research-grade sermorelin fit?
Outside every lawful route, and FDA has tested the point on sermorelin itself. A warning letter dated 10 December 2024 to a seller of research-labelled products named seven products including sermorelin. Despite labelling reading "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE," FDA held the products were unapproved new drugs violating sections 505(a) and 301(d) of the Food, Drug and Cosmetic Act, because website evidence established human intended use. The disclaimer described the label, not the transaction.
The enforcement in Peptigrity's record runs against sellers, and this page does not address the position of any purchaser. The wider market is described on the grey market overview.
What did the FDA approvals cover, and what do they not?
Two narrow uses, neither of them current. Geref Diagnostic was approved to evaluate the pituitary's growth-hormone-secretory capacity, and Geref to treat idiopathic growth-hormone deficiency in children. Adult use was never approved, and Peptigrity's three-way comparison records that sermorelin's therapeutic evidence is thinner than its approval implies: the one adult trial found no change in fat or lean mass at six weeks.
The withdrawal history is often misreported. EMD Serono discontinued both products in 2008 for commercial reasons, as the market shifted toward recombinant human growth hormone, and FDA formally determined in 2013 that Geref was not withdrawn for reasons of safety or effectiveness. None of that bears on sport: WADA names sermorelin at S2.2.4, prohibited at all times. Sermorelin sits in the growth hormone category, and its dated regulatory context is in the FDA regulation timeline for 2025–2026.
What does Peptigrity's lab record show for sermorelin?
As of 21 September 2026, Peptigrity holds 225 independent lab tests of sermorelin, averaging 99.35% HPLC purity (the average covers the 222 tests that report a purity figure), from 17 laboratories. Every result is listed on the sermorelin lab tests page, with the compound record on the sermorelin compound page, per-milligram prices on the sermorelin price comparison and volume arithmetic in the sermorelin calculator.
Read those figures for what they are. A purity percentage measures what is in a vial; it says nothing about legal status. Sermorelin also sits 10 daltons from Mod GRF (1-29), at 3,357.9 against 3,367.9, which is too close for a rounded nominal mass to separate them. The certificates are ones shops chose to publish, a selection bias Peptigrity states openly.
Frequently Asked Questions
Was sermorelin ever FDA approved?
Yes, twice: Geref Diagnostic (NDA 019863) in December 1990 and Geref (NDA 020443) in September 1997. Both products were discontinued in 2008 and the approvals formally withdrawn in 2009, so no FDA-approved sermorelin product is marketed today.
Why was Geref discontinued?
For commercial reasons. The paediatric growth-hormone-deficiency market shifted toward recombinant human growth hormone, and FDA determined in 2013 that Geref was not withdrawn for reasons of safety or effectiveness.
Is sermorelin legal in the United States?
Sermorelin can be compounded by a US pharmacy for a named patient on a licensed physician's prescription, under the component-of-an-approved-drug prong. Research-labelled sermorelin sold for human use is a different matter: FDA's 10 December 2024 warning letter held such products to be unapproved new drugs. This page does not address any individual's legal position.
Do you need a prescription for sermorelin?
Yes, for pharmacy supply. Compounded sermorelin is prepared for a named patient with a prescription from a licensed physician. Research-grade material is not a prescription product.
Is sermorelin on FDA's Category 2 list?
No. Sermorelin is absent from FDA's Category 2 list on the page current 22 April 2026, and FDA's 503B documentation footnotes "Sermorelin Acetate" as a component of FDA-approved drugs.
Is sermorelin banned by WADA?
Yes. WADA's 2026 Prohibited List names sermorelin at section S2.2.4 among growth-hormone-releasing factors, prohibited at all times. A prescription does not change that; only a therapeutic use exemption from an anti-doping organisation can.
Sources
External documents cited on Peptigrity's own pages for the statements above.
FDA — Certain bulk drug substances for use in compounding that may present significant safety risks (page current 22 April 2026)
WADA — Prohibited List (2026)
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Sermorelin's status row, lab record and listings live on the sermorelin compound page. How its position compares with other compounds, axis by axis and country by country, is in are peptides legal? Regulatory status by country.